Oscar Health (OSCR) is positioned as the stronger investment compared to Molina Healthcare (MOH), driven by robust 46% membership growth, 70% revenue increase, a 20% revenue CAGR target through 2027, and a lower valuation multiple. Molina faces headwinds from rising medical costs, enrollment challenges, and portfolio restructuring, with a projected 2027 exit from its MAPD business and $1 billion marketplace premium reduction.

ASX Limited - Unsponsored ADR (ASXFY) is significantly outperforming the Finance sector year-to-date, returning 26.3% compared to the sector average of 3.3%. The stock holds a Zacks Rank #1 (Strong Buy) with analyst sentiment improving, as consensus earnings estimates have risen 9.9% in the past quarter. Oscar Health, Inc. (OSCR) is another standout performer in the Finance sector with 132.9% year-to-date returns and a Zacks Rank #1 rating.

Despite recent market volatility driven by AI concerns, rising rates, and geopolitical tensions, three stocks with strong Zacks Rank #1 ratings stand out: Cinemark benefits from theater attendance recovery and pricing power, Oscar Health is transitioning to profitability with surging membership growth, and Heico demonstrates consistent aerospace and defense sector strength. All three show improving earnings estimates and constructive technical setups independent of AI boom dependency.

Oscar Health (OSCR) closed at $33.47, down 2.48% on the trading day. The company is rated Zacks Rank #1 (Strong Buy) with an upcoming earnings release on November 5, 2026. Analysts expect EPS of -$0.11 and revenue of $4.72 billion for the quarter, with full-year forecasts of $1.83 EPS and $18.81 billion revenue. The stock trades at a Forward P/E of 18.72, above the industry average of 10.07, with a PEG ratio of 0.38.

Amid market volatility triggered by rising interest rates, inflation concerns, and AI sector weakness, three stocks with strong earnings momentum stand out: Cinemark benefits from theater attendance recovery and pricing power, Oscar Health is transitioning to profitability with surging membership growth, and HEICO demonstrates consistent aerospace and defense sector strength. All three carry Zacks Rank #1 ratings and offer exposure outside the dominant AI investment theme.

Stock markets declined following a higher-than-expected CPI inflation report. The article highlights three stocks with Zacks Rank #1 buy ratings: Petco Health and Wellness (WOOF), Five Below (FIVE), and Oscar Health (OSCR), all showing strong earnings estimate increases and favorable PEG ratios compared to their respective industry averages.

Oscar Health (OSCR) closed at $34.32, up 1.57%, outperforming the S&P 500's decline. The company has gained 4.16% over the past month. With an upcoming earnings report expected November 5, 2026, analysts project EPS of -$0.11 and revenue of $4.72 billion. For the full fiscal year, projections show EPS of $1.83 and revenue of $18.81 billion. OSCR holds a Zacks Rank #1 (Strong Buy) rating with consensus EPS projections up 18.79% in the past 30 days, though it trades at a premium valuation with a Forward P/E of 18.43 versus the industry average of 10.09.

Oscar Health (OSCR), a healthcare technology company offering ACA health plans, has been identified as a strong momentum stock with a Zacks Rank #1 (Strong Buy) rating and a VGM Score of A. The company has seen three upward earnings estimate revisions in the last 60 days, with consensus estimates increasing to $1.83 per share for fiscal 2026, and shares are up 4.2% over the past four weeks.

Oscar Health, Inc. (OSCR) has been added to the Zacks Rank #1 (Strong Buy) list on September 23, 2026. The healthcare technology company has received upward earnings estimate revisions from three analysts, with consensus estimates increasing to $1.83 per share. Analysts expect 208.3% earnings growth and 60.8% revenue growth for the current fiscal year, with the stock up 4.2% over the past four weeks.

Oscar Health (OSCR) is highlighted as an attractive investment opportunity combining momentum with value. The stock has gained 4.2% over four weeks and 9.8% over 12 weeks, with a beta of 2.47 indicating high volatility. Despite strong momentum metrics and a Zacks Rank #1 (Strong Buy) rating driven by upward earnings estimate revisions, OSCR trades at a reasonable valuation with a Price-to-Sales ratio of 0.68, suggesting significant upside potential.

Oscar Health raised its 2026 operating earnings guidance to $500M-$700M from $250M-$450M, driven by improved medical loss ratios (75% from 83%), disciplined pricing, and technology-driven expense efficiency. However, the company faces headwinds in the second half including 2%-4% monthly churn, rising medical costs, and open-enrollment spending. Revenue guidance remained unchanged at $18.7B-$19B.

Oscar Health (OSCR) demonstrates impressive growth with Q2 revenues surging 70.4% to $4.9 billion and membership jumping 46.2% to 2.96 million, significantly outpacing a contracting ACA market. However, the stock trades at a premium valuation of 5.5X tangible book value versus the sub-industry's 1.2X, leaving limited room for disappointment. Execution risks include rising churn rates, increasing medical costs, and favorable reserve items that may not repeat, though the company maintains a strong capital base of $10.2 billion.